Publications

• Use of CD19-targeted immune modulation to eradicate AAV-neutralizing antibodies.
  Mol Ther
  03/08/2025 Authors: Doshi BS; Markmann CA; Novak N; Juarez Rojas S; Davidson R; Chau JQ; Wang W; Carrig S; Martos Rus C; Samelson-Jones BJ
• Intron 22 inversions: cross-reactive material or no cross-reactive material?
  J Thromb Haemost Volume: 22 Page(s): 3400 - 3402
  12/01/2024 Authors: Doshi BS
• Coagulation factor VIII: biological basis of emerging hemophilia A therapies.
  Blood Volume: 144 Page(s): 2185 - 2197
  11/21/2024 Authors: Samelson-Jones BJ; Doshi BS; George LA
• Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.
  Blood Volume: 144 Page(s): 1230 - 1235
  09/12/2024 Authors: Lee K; Chau JQ; Suber YB; Sternberg AR; Pishko AM; George LA; Bhoj VG; Doshi BS; Samelson-Jones BJ
• RNAing toward a new therapy for hemophilia.
  Blood Volume: 143 Page(s): 2219 - 2221
  05/30/2024 Authors: Doshi BS; Sidonio RF
• AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life.
  Mol Ther Methods Clin Dev Volume: 32 Page(s): 101205
  03/14/2024 Authors: Doshi BS; Samelson-Jones BJ; Nichols TC; Merricks EP; Siner JL; French RA; Lee BJ; Arruda VR; Callan MB
• Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog.
  Mol Ther Methods Clin Dev Volume: 31 Page(s): 101159
  12/14/2023 Authors: Van Gorder L; Doshi BS; Willis E; Nichols TC; Cook E; Everett JK; Merricks EP; Arruda VR; Bushman FD; Callan MB
• Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.
  J Thromb Haemost Volume: 21 Page(s): 3477 - 3489
  12/01/2023 Authors: Cao W; Trask AR; Bignotti AI; George LA; Doshi BS; Sabatino DE; Yada N; Zheng L; Camire RM; Zheng XL
• Hemolysis After Medication Exposure in Pediatric Patients With G6PD Deficiency.
  J Pediatr Hematol Oncol Volume: 44 Page(s): 261 - 263
  07/01/2022 Authors: Doshi BS; Kamdar A; Lambert MP; Obstfeld AE
• Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice.
  J Blood Med Volume: 13 Page(s): 255 - 265
  01/01/2022 Authors: Pishko AM; Doshi BS
• Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.
  Haemophilia Volume: 27 Page(s): e551 - e553
  07/01/2021 Authors: Doshi BS; Witmer CM
• Diagnosis and Management of Pediatric Venous Thromboembolism: New Therapies on the Horizon.
  Pediatr Emerg Care Volume: 37 Page(s): 273 - 279
  05/01/2021 Authors: Doshi BS; Ellison AM
• B cell-activating factor modulates the factor VIII immune response in hemophilia A.
  J Clin Invest Volume: 131
  04/15/2021 Authors: Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
• Combined anti-CD20 and mTOR inhibition with factor VIII for immune tolerance induction in hemophilia A patients with refractory inhibitors.
  J Thromb Haemost Volume: 18 Page(s): 848 - 852
  04/01/2020 Authors: Doshi BS; Raffini LJ; George LA
• Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century.
  Mediterr J Hematol Infect Dis Volume: 12 Page(s): e2020069
  01/01/2020 Authors: Arruda VR; Doshi BS
• Clingen Coagulation Factor Deficiency Variant Curation Expert Panel: Meeting the Need for Recommendations to Curate Variants in the Coagulation Factor Genes
  Volume: 134
  11/13/2019 Authors: Mohan S; Lee K; Carcao M; Doshi BS; Downes K; Kemball-Cook G; Leebeek F; McCreery J; Miller CH; Payne AB
• Utility of repeat testing in the evaluation for von Willebrand disease in pediatric patients.
  J Thromb Haemost Volume: 17 Page(s): 1838 - 1847
  11/01/2019 Authors: Doshi BS; Rogers RS; Whitworth HB; Stabnick EA; Britton J; Butler RB; Obstfeld AE; Witmer CM
• Gene therapy for hemophilia: Progress to date and challenges moving forward.
  Transfus Apher Sci Volume: 58 Page(s): 602 - 612
  10/01/2019 Authors: Gollomp KL; Doshi BS; Arruda VR
• Gene therapy for hemophilia: what does the future hold?
  Ther Adv Hematol Volume: 9 Page(s): 273 - 293
  09/01/2018 Authors: Doshi BS; Arruda VR
• Iliopsoas hematoma in a patient with sickle cell disease.
  Pediatr Blood Cancer Volume: 65 Page(s): e27040
  07/01/2018 Authors: Zielonka B; Cohen AR; Smith-Whitley K; Doshi BS
• Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130(21):2251-2256.
  Blood Volume: 131 Page(s): 2995
  06/28/2018
• Emerging therapies for hemophilia: controversies and unanswered questions.
  F1000Res Volume: 7
  01/01/2018 Authors: Arruda VR; Doshi BS; Samelson-Jones BJ
• Novel approaches to hemophilia therapy: successes and challenges.
  Blood Volume: 130 Page(s): 2251 - 2256
  11/23/2017 Authors: Arruda VR; Doshi BS; Samelson-Jones BJ
• Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain Injury
  BLOOD Volume: 124
  12/06/2014 Authors: Doshi BS; Meeks SL; Hendrickson JE; Reisner A; Leong T; Winkler AM; Meyer E
• Concomitant a novel ALAS2 mutation and GATA1 mutation in a newborn: a case report and review of the literature.
  Am J Blood Res Volume: 4 Page(s): 41 - 45
  01/01/2014 Authors: Doshi BS; Abramowsky C; Briones M; Bunting ST
• A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
  Blood Volume: 120 Page(s): 2512 - 2520
  09/20/2012 Authors: Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
• Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
  PLoS One Volume: 7 Page(s): e48172
  01/01/2012 Authors: Doshi BS; Gangadharan B; Doering CB; Meeks SL
• Factor VIII Supplementation Improves Recombinant VIIa Initiated Thrombin Generation in Hemophilia A Inhibitor Patient Plasmas
  Volume: 118 Page(s): 17 - 17
  11/18/2011 Authors: Doshi B; Cox C; Gangadharan B; Doering CB; Meeks SL